Back to Mobile View
Subscribe to the CrunchBase Daily for the latest on Fundings, Acquisitions, and Startup Events

General Information

Websitecormedix.com
Twitter@cormedix
CategoryBioTech
Phone908-517-9500
Employees
Founded2006
DescriptionCommercialize products for the Treatment

Offices

Bridgewater, USA
745 Route 202-206, Suite 303
Bridgewater, NJ, 08807
USA

People

CEO
CFO
Chief Scientific Officer

Funding

TOTAL $5.62M
FUNDING TOTAL $5.62M
Venture Round, 11/2009
$2.62M
Seed, 10/2013
$3M
DEBT TOTAL $850k
Debt, 10/2012
$850k

Tags

CorMedix

CorMedix Inc. is a specialty pharmaceutical company that develops and seeks to commercialize products for the treatment of cardiac, renal and infectious diseases. Specifically, our goal is to treat human disease by reducing commonly associated renal, cardiovascular, metabolic and infectious complications. Our therapeutic candidates may be small molecules, biologics, chemical entities, devices and/or diagnostics (molecular/lab tests) that enable targeted therapy in these areas.

CorMedix has received CE Mark approval for Neutrolin®, a catheter lock solution for the prevention of catheter related bloodstream infections and maintenance of catheter patency in tunneled, cuffed, central venous catheters used for vascular access in hemodialysis patients. Our goal is to provide risk mitigation solutions for central venous catheters (CVCs) in a variety of important indications.

Recent Milestones

Videos

Screenshots

CorMedix screenshot
Above: Home Page
Uploaded: 7/17/13

Sources

  1. SEC (sec.gov) [edit]
  2. SEC (sec.gov) [edit]
  3. CorMedix to raise $3M in concurrent offerings (njbiz.com) [edit]
Edit This Page
Last Edited 3/20/14

Revision History RSS Picture

Sharing

Share this page on Twitter or Facebook:
Or copy this code to embed a widget: customize ┬╗

External Links

CrunchBase API

Sponsors



Become a Sponsor
Terms of Service | Privacy Policy | Licensing Policy